Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00788 ...
Drug Name Naproxen
Molecular Weight 230.2592
Molecular Formula C14H14O3
CAS Number 22204-53-1
SMILES COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O
External Links
DRUGBANK DB00788
PubChem Compound 156391
PDR 2069
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability -4.83 - -4.83 - ADME Research, USCD
Log P 3.18 - 3.18 - HANSCH,C ET AL. (1995)
Melting Point 152.0 ℃ 152 ℃ MSDS Label
Water Solubility 15.9 mg/L 15.9 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
pKa 4.15 - 4.15 - SANGSTER (1994)
Log S -4.16 - -4.16 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % 100 % PO, oral; Rectal Administration; DRUGBANK
AUC 1446000.0 ng.h/ml 1446.0 mcg.h/ml PO, oral; Rectal Administration; immediate release formulation; DRUGBANK
AUC 1448000.0 ng.h/ml 1448.0 mcg.h/ml PO, oral; Rectal Administration; extended release formulation; DRUGBANK
AUC 845000.0 ng.h/ml 845.0 mcg.h/ml PO, oral; Derivative; DRUGBANK
AUC 767000.0 ng.h/ml 767.0 mcg.h/ml PO, oral; Rectal Administration; different study; DRUGBANK
Bioavailability 99.0 % 99.0 % The Pharmacological Basis of Therapeutics
C Max 95700.0 ng/ml 94-97.4 mcg/ml PO, oral; Rectal Administration; DRUGBANK
C Max 37.0 null 37.0 null Tablet, PO, oral; immediate release formulation; adults; The Pharmacological Basis of Therapeutics
C Max 94.0 null 94.0 null Tablet, PO, oral; extended release formulation; adults; The Pharmacological Basis of Therapeutics
C Max 55000.0 ng/ml 55±14 mcg/ml Liquid; Children; patients; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2 h PO, oral; Rectal Administration; DRUGBANK
T Max 3.0 h 3 h PO, oral; Rectal Administration; DRUGBANK
T Max 5.0 h 5 h PO, oral; Rectal Administration; DRUGBANK
T Max 4.0 h 4 h PO, oral; Derivative; DRUGBANK
T Max 1.9 h 1.9 h PO, oral; Rectal Administration; different study; DRUGBANK
T Max 5.0 h 5 h combination drug use; DRUGBANK
T Max 1.0 h 1 h PO, oral; Derivative; DRUGBANK
T Max 3.0 h 2-4 h Tablet, PO, oral; immediate release formulation; adults; The Pharmacological Basis of Therapeutics
T Max 5.0 h 5.0 h Tablet, PO, oral; extended release formulation; adults; The Pharmacological Basis of Therapeutics
T Max 2.2 h 2.2±2.1 h Liquid; Children; patients; The Pharmacological Basis of Therapeutics
Clearance 0.007800 L/h/kg 0.13 ml/min/kg DRUGBANK
Clearance 0.007800 L/h/kg 0.13±0.02 ml/min/kg apparent clearance; hydrolysis; hydrolysis; Children → ;Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;rheumatoid arthritis ↑ ; The Pharmacological Basis of Therapeutics
Clearance 0.004200 L/h/kg 0.07 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.16 L/kg 0.16 L/kg DRUGBANK
Volume of Distribution 0.16 L/kg 0.16±0.02 L/kg Apparent volume of distribution; hydrolysis; hydrolysis; Elderly → ;RD, renal impairment, Renal disease，including uremia ↑ ;rheumatoid arthritis ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.0900 L/kg 0.09 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 14.5 h 12-17 h elimination half-life; DRUGBANK
Half-life 14.0 h 14±1 h Children → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 16.6 h 16.63 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 95.0 % ~95 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 5.0 % <5 % Faeces excretion; PO, oral; DRUGBANK
Eliminate Route 5.5 % 5-6 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 99.0 % >99 % DRUGBANK
Protein Binding 99.7 % 99.7±0.1 % Elderly ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;rheumatoid arthritis ↓ ;hypoalbuminemia Alb ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 20.0 mg/kg/day 20 mg/kg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for children 1000.0 mg/day 1000 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for children 660.0 mg/day 660 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for children 20.0 mg/kg/day 20 mg/kg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for children 1000.0 mg/day 1000 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adolescents 1500.0 mg/day 1500 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adolescents 1650.0 mg/day 1650 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adolescents 660.0 mg/day 660 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adults 1500.0 mg/day 1500 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adults 1650.0 mg/day 1650 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for adults 660.0 mg/day 660 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for geriatric 1500.0 mg/day 1500 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for geriatric 1650.0 mg/day 1650 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR
Max dose for geriatric 660.0 mg/day 660 mg/day PO, oral Anaprox/EC-Naprosyn/Naprosyn (naproxen); (naproxen sodium) PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1